- Home
- TBBB vs GH Comparison
TBBB vs GH Comparison
Compare TBBB & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBBB
- GH
- Stock Information
- Founded
- TBBB 2004
- GH 2011
- Country
- TBBB Mexico
- GH United States
- Employees
- TBBB N/A
- GH N/A
- Industry
- TBBB
- GH Medical Specialities
- Sector
- TBBB
- GH Health Care
- Exchange
- TBBB NYSE
- GH Nasdaq
- Market Cap
- TBBB 3.6B
- GH 4.3B
- IPO Year
- TBBB 2024
- GH 2018
- Fundamental
- Price
- TBBB $28.99
- GH $34.53
- Analyst Decision
- TBBB Buy
- GH Strong Buy
- Analyst Count
- TBBB 7
- GH 15
- Target Price
- TBBB $29.86
- GH $39.93
- AVG Volume (30 Days)
- TBBB 839.7K
- GH 1.5M
- Earning Date
- TBBB 02-12-2025
- GH 11-06-2024
- Dividend Yield
- TBBB N/A
- GH N/A
- EPS Growth
- TBBB N/A
- GH N/A
- EPS
- TBBB 0.12
- GH N/A
- Revenue
- TBBB $2,727,305,465.00
- GH $692,256,000.00
- Revenue This Year
- TBBB $35.22
- GH $32.23
- Revenue Next Year
- TBBB $27.58
- GH $16.90
- P/E Ratio
- TBBB $246.14
- GH N/A
- Revenue Growth
- TBBB 29.70
- GH 29.20
- 52 Week Low
- TBBB $18.71
- GH $15.81
- 52 Week High
- TBBB $35.22
- GH $38.53
- Technical
- Relative Strength Index (RSI)
- TBBB N/A
- GH 58.28
- Support Level
- TBBB N/A
- GH $34.20
- Resistance Level
- TBBB N/A
- GH $36.24
- Average True Range (ATR)
- TBBB 0.00
- GH 1.40
- MACD
- TBBB 0.00
- GH -0.54
- Stochastic Oscillator
- TBBB 0.00
- GH 12.70
About TBBB BBB FOODS INC
BBB Foods Inc is a company offering grocery hard discount model in Mexico. Also that operates through three subsidiaries namely Tiendas Tres B , Tiendas BBB and Desarrolladora Tres BSA de CV of which the main activity of Tiendas Tres B is the sale, purchase, distribution and marketing of all types of products, items and goods, as well as the establishment, and operation of individual stores and distribution centers for the sale of such products.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.